PULMONOLOGY

Description


The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B) followed by safety extension in participants with pulmonary arterial hypertension.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Title
Description


A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Kunal Gada, StatCare Medical Group
Listing Category
Description


A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study of Efficacy and Safety of Treprostinil Palmitil Inhalation Powder inParticipants with Idiopathic Pulmonary Fibrosis (IPF) – PALM-IPF

Study Status
Upcoming Trial
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Listing Category
Study Status
Upcoming Trial
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Description


An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Description


A randomized, double-blinded, placebo-controlled, multinational, phase 3 study of the efficacy and safety of inhaled Treprostinil in subjects with progressive pulmonary fibrosis

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Scroll to Top